1183 related articles for article (PubMed ID: 12869959)
1. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
[TBL] [Abstract][Full Text] [Related]
2. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
[TBL] [Abstract][Full Text] [Related]
3. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases.
Georges GE; Maris M; Sandmaier BM; Malone DG; Feinstein L; Niederweiser D; Shizuru JA; McSweeney PA; Chauncey TR; Agura E; Little MT; Sahebi F; Hegenbart U; Pulsipher MA; Bruno B; Forman S; Woolfrey AE; Radich JP; Blume KG; Storb R
Int J Hematol; 2002 Aug; 76 Suppl 1():184-9. PubMed ID: 12430851
[TBL] [Abstract][Full Text] [Related]
4. Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.
Spinner MA; Kennedy VE; Tamaresis JS; Lavori PW; Arai S; Johnston LJ; Meyer EH; Miklos DB; Muffly LS; Negrin RS; Rezvani AR; Shizuru JA; Weng WK; Hoppe RT; Strober S; Lowsky R
Blood Adv; 2019 Aug; 3(16):2454-2464. PubMed ID: 31427277
[TBL] [Abstract][Full Text] [Related]
5. Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes.
Pantin J; Tian X; Shah AA; Kurlander R; Ramos C; Cook L; Khuu H; Stroncek D; Leitman S; Barrett J; Donohue T; Young NS; Geller N; Childs RW
Am J Hematol; 2013 Oct; 88(10):874-82. PubMed ID: 23813900
[TBL] [Abstract][Full Text] [Related]
6. Graft versus host disease after stem cell allotransplantation with low-dose total body irradiation, fludarabine, and antithymocyte globulin.
Grosskreutz C; Scigliano E; Osman K; Isola L
Transplantation; 2007 Sep; 84(5):598-604. PubMed ID: 17876272
[TBL] [Abstract][Full Text] [Related]
7. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation.
Deeg HJ; Amylon ID; Harris RE; Collins R; Beatty PG; Feig S; Ramsay N; Territo M; Khan SP; Pamphilon D; Leis JF; Burdach S; Anasetti C; Hackman R; Storer B; Mueller B
Biol Blood Marrow Transplant; 2001; 7(4):208-15. PubMed ID: 11349807
[TBL] [Abstract][Full Text] [Related]
8. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure.
Chewning JH; Castro-Malaspina H; Jakubowski A; Kernan NA; Papadopoulos EB; Small TN; Heller G; Hsu KC; Perales MA; van den Brink MR; Young JW; Prockop SE; Collins NH; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2007 Nov; 13(11):1313-23. PubMed ID: 17950918
[TBL] [Abstract][Full Text] [Related]
10. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
12. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
[TBL] [Abstract][Full Text] [Related]
13. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
14. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
15. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
Kottaridis PD; Milligan DW; Chopra R; Chakraverty RK; Chakrabarti S; Robinson S; Peggs K; Verfuerth S; Pettengell R; Marsh JC; Schey S; Mahendra P; Morgan GJ; Hale G; Waldmann H; Ruiz de Elvira MC; Williams CD; Devereux S; Linch DC; Goldstone AH; MacKinnon S
Cytotherapy; 2001; 3(3):197-201. PubMed ID: 12171726
[TBL] [Abstract][Full Text] [Related]
16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
18. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
Feinstein L; Sandmaier B; Maloney D; McSweeney PA; Maris M; Flowers C; Radich J; Little MT; Nash RA; Chauncey T; Woolfrey A; Georges G; Kiem HP; Zaucha JM; Blume KG; Shizuru J; Niederwieser D; Storb R
Ann N Y Acad Sci; 2001 Jun; 938():328-37; discussion 337-9. PubMed ID: 11458521
[TBL] [Abstract][Full Text] [Related]
19. Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning.
Kobbe G; Schneider P; Aivado M; Zohren F; Schubert D; Fenk R; Neumann F; Kronenwett R; Pape H; Rong A; Royer-Pokora B; Hildebrandt B; Germing U; Gattermann N; Heyll A; Haas R
Exp Hematol; 2002 Nov; 30(11):1346-53. PubMed ID: 12423689
[TBL] [Abstract][Full Text] [Related]
20. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]